Compare WEYS & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEYS | CABA |
|---|---|---|
| Founded | 1906 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.9M | 319.6M |
| IPO Year | 1995 | 2019 |
| Metric | WEYS | CABA |
|---|---|---|
| Price | $31.86 | $3.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.57 |
| AVG Volume (30 Days) | 4.7K | ★ 2.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.50 | N/A |
| Revenue | ★ $290,290,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.99 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.51 | $0.99 |
| 52 Week High | $34.63 | $3.78 |
| Indicator | WEYS | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 56.42 | 63.08 |
| Support Level | $31.06 | $2.11 |
| Resistance Level | $33.40 | $3.73 |
| Average True Range (ATR) | 0.81 | 0.30 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 74.19 | 67.11 |
Weyco Group Inc is a company, engaged in the manufacturing, designing, and distribution of footwear. The company designs and markets footwear for men, women, and children. It markets its apparel, accessories, and footwear under the brand names of Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters, and Forsake. The company organizes its business into two segments; the North American wholesale operations and the North American retail operations. The majority of the company's revenue is generated from the wholesale segment under which its products are sold to footwear, department, and specialty stores, as well as e-commerce retailers. The company has operational footprints in the United States which generates key revenue, Canada, Asia, South Africa, and Australia.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.